Skip to main content
SCANCELL HOLDINGS PLC logo

SCANCELL HOLDINGS PLC — Investor Relations & Filings

Ticker · SCLP ISIN · GB00B63D3314 LEI · 2138008RXEG856SNP666 IL Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2023-01-25 Interim / Quarterly Rep…
Country GB United Kingdom
Listing IL SCLP

About SCANCELL HOLDINGS PLC

https://www.scancell.co.uk/

Scancell Holdings PLC is a clinical-stage company developing novel active immunotherapies for the treatment of cancer. Its approach focuses on enhancing long-lasting, tumor-specific immunity to address significant unmet needs in oncology, particularly for hard-to-treat cancers. The company leverages its proprietary technology platforms, Immunobody®, Moditope®, and AvidiMab™, to create targeted, off-the-shelf therapies. The Immunobody® platform generates DNA-based immunotherapies, with its lead candidate, iSCIB1+, targeting advanced melanoma. The Moditope® platform develops peptide-based therapies, with a lead product showing encouraging Phase 2 data in a broad range of solid tumors. Scancell aims to deliver treatments that are safe, effective, easily administered, and accessible to patients.

Recent filings

Filing Released Lang Actions
Interim Results
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Results for the 6 months ended 31 October 2022' for Scancell Holdings Plc. It contains detailed financial statements, including a loss for the period, cash balances, and a comprehensive management discussion and analysis of clinical trials and corporate developments. As it covers a period shorter than a full fiscal year and includes substantive financial data and analysis, it is classified as an Interim/Quarterly Report. H1 2023
2023-01-25 English
Notice of Interim Results
Report Publication Announcement Classification · 99% confidence The document is very short (3517 characters) and its primary purpose is to announce *when* the company expects to release its financial results. The text explicitly states: 'Scancell Holdings plc... expects to announce its interim results for the six month period ended 31 October 2022 on 25 January 2023.' This fits the definition of a Report Publication Announcement (RPA), which signals the upcoming release of a report (in this case, the Interim Results, which would typically be an IR filing). Since this document is only the announcement of the publication date, RPA is the most appropriate classification based on the 'MENU VS MEAL' rule.
2023-01-18 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1939 characters) and contains the header 'RNS Number : 8091I' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content describes a 'Second Price Monitoring Extension' for a security, which is a specific, short-form regulatory market announcement regarding trading suspension/extension. This type of brief, market-specific operational update that doesn't fit into standard financial reporting categories (like 10-K, ER, IR) is best classified as a general Regulatory Filing (RNS), as it is distributed via the RNS system.
2022-12-06 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1922 characters) and contains the header 'RNS Number : 8080I'. It announces a 'Price Monitoring Extension' related to trading on the London Stock Exchange and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This indicates it is a general regulatory announcement disseminated via the RNS system, rather than a specific financial report like an ER, 10-K, or IR. Since it is a general regulatory announcement that doesn't fit the specific categories (like DIRS, DIV, or DLST), the most appropriate fallback category is Regulatory Filings (RNS).
2022-12-06 English
Result of Annual General Meeting
AGM Information Classification · 99% confidence The document explicitly states it is an announcement regarding the 'Result of Annual General Meeting' (AGM). It confirms that 'all resolutions proposed at the Annual General Meeting held today were duly passed.' This directly corresponds to the definition of AGM Information (AGM-R). Although it is a short announcement, the content is the result itself, not just an announcement that a report is forthcoming, making AGM-R a better fit than RPA or RNS, as it is a specific outcome announcement.
2022-11-21 English
Licenses Vaccitech technology to advance Modi-2
M&A Activity Classification · 99% confidence The document begins with an 'RNS Number' and is dated '07 November 2022'. It announces a specific corporate action: Scancell Holdings Plc in-licensing technology from Vaccitech to advance a product (Modi-2). The text explicitly states, 'This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).' and concludes with boilerplate text from RNS, the news service of the London Stock Exchange, identifying itself as a Primary Information Provider. This structure is characteristic of a general regulatory news service announcement, which fits the definition of 'Regulatory Filings' (RNS) as a broad category for official market disclosures that aren't covered by more specific codes like 10-K, ER, or DIV. Since it is a general news release distributed via the RNS system, RNS is the most appropriate classification.
2022-11-07 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.